Exact sciences corporation stock.

06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...Exact Sciences (EXAS) Stock Price & Analysis ; Previous Close$66.3 ; Volume2.13M ; Average Volume (3M)1.45M ; Market Cap. $11.99B ; Enterprise Value$13.82B.

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...Jun 7, 2023 · The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...

Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!Nov 22, 2023 · Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...

Exact Sciences Corporation issued to certain of the selling stockholders of Paradigm an aggregate of 381,047 shares of common stock as initial merger consideration for their ownership in Paradigm. In addition, Exact Sciences Corporation withheld 45,338 shares of common stock payable as additional merger consideration to such selling ...Adjusted EBITDA for the three and six months ended June 30, 2021 has been updated accordingly for comparative purposes. Of the $64.5 million and $60.8 million incurred for the three months ended June 30, 2022 and 2021, $56.4 million and $53.9 million is related to stock-based compensation, respectively, and $8.1 million and $6.9 million is ...Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Exact Sciences Corporation (EXAS) : Free Stock Analysis Report. To read this article on Zacks.com click here.About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Exact Sciences exited third-quarter 2021 with cash and cash equivalents, and marketable securities of $1.22 billion compared with $1.31 billion at the end of second-quarter 2021.

EXACT SCIENCES CORPORATION. Selected Unaudited Financial Information. EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended March 31, (In thousands) ... Stock-based compensation (2) 65,481. 71,191. Investment expense (income) 1,487 (31,188) Acquisition and integration costs (3) …

TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis. Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...EXACT SCIENCES CORPORATION. Selected Unaudited Financial Information. EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended March 31, (In thousands) ... Stock-based compensation (2) 65,481. 71,191. Investment expense (income) 1,487 (31,188) Acquisition and integration costs (3) …Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …10-Jan-2023 ... The most important factor in Exact Sciences' business outlook is its commitment to developing innovative new technologies that improve cancer ...Business intelligence is what S&P ratings are all about. This global corporation provides credit ratings on investments, including bonds and the stock market. Before you can understand what a good rating is, it helps to understand the origi...

16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...

Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Dec 1, 2023 · Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ... 04-Jan-2023 ... As illustrated in our open-source model, shares of Exact Sciences could compound at an average annual rate of 25%, reaching $140 by 2027.MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's …All. Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress. PR Newswire Oct 20, 2023 10:08pm.See Exact Sciences Corporation (EXAS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Exact Sciences Corporation. 01 Aug, 2023, 16:05 ET. Reports record results, generates positive free cash flow, raises full-year guidance. Second-quarter 2023 highlights. Total second quarter ...

MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical Oncology (ESMO) Congress, October 20-24, in Madrid, Spain.

On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 7.65% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ... Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. All. Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.EXACT Sciences News: This is the News-site for the company EXACT Sciences on Markets Insider Indices Commodities Currencies StocksExact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...EXACT Sciences News: This is the News-site for the company EXACT Sciences on Markets Insider Indices Commodities Currencies StocksExact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 7.65% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on …30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ...MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended ...But EXAS stock toppled 4.3% on Wednesday after the company announced the Blue-C results. The tumble is likely related to the new product's minimal improvement in finding precancerous polyps. Those ...Analyst Forecast. According to 17 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $92.07, which is an increase ...View live Exact Sciences Corporation chart to track its stock's price action. Find market predictions, EXAS financials and market news.Instagram:https://instagram. emerging markets bond etfmolina healthcare ratingscrowdsourcing real estatejewl stock 07-Oct-2020 ... What is Exact Sciences Corporation stock price? On 2023-12-01, Exact Sciences Corporation (EXAS-Q) stock closed at a price of $67.03.Find real-time EXAS - Exact Sciences Corp stock quotes, company profile, news and forecasts from CNN Business. cheapest stocks that pay dividendsmoney oil Get the latest news and real-time alerts from Exact Sciences Corporation (EXAS) stock at Seeking Alpha. ... EXAS Exact Sciences Corporation. Latest News. Follow $65.82-0.17 (-0.26%) ... tbill ladder Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov 02 + 1 more update. Forecast to breakeven in 2025 Oct 26. No longer forecast ... Lead Independent Director exercised options to buy US$363k worth of stock. Jan 19. Insider notifies of intention to sell stock Jan 13. An Intrinsic Calculation For Exact ...Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... Story continues. SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and ...